IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v32y2014i3p231-234.html
   My bibliography  Save this article

The Role of Health Economics and Outcomes Research in Health Care Reform in China

Author

Listed:
  • Wannian Liang
  • Jipan Xie
  • Hongpeng Fu
  • Eric Wu

Abstract

No abstract is available for this item.

Suggested Citation

  • Wannian Liang & Jipan Xie & Hongpeng Fu & Eric Wu, 2014. "The Role of Health Economics and Outcomes Research in Health Care Reform in China," PharmacoEconomics, Springer, vol. 32(3), pages 231-234, March.
    • Handle: RePEc:spr:pharme:v:32:y:2014:i:3:p:231-234
    DOI: 10.1007/s40273-014-0141-2
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-014-0141-2
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-014-0141-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Judy Xu & Gordon Liu & Guoying Deng & Lin Li & Xianjun Xiong & Kisalaya Basu, 2015. "A Comparison of Outpatient Healthcare Expenditures Between Public and Private Medical Institutions in Urban China: An Instrumental Variable Approach," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 270-279, March.
    2. Tan Chongqing & Peng Liubao & Zeng Xiaohui & Li Jianhe & Wan Xiaomin & Chen Gannong & Wang Siying & Ouyang Lihui & Zhao Ziying, 2014. "Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline," PharmacoEconomics, Springer, vol. 32(3), pages 235-243, March.
    3. Mitton, Craig R. & McMahon, Meghan & Morgan, Steve & Gibson, Jennifer, 2006. "Centralized drug review processes: Are they fair?," Social Science & Medicine, Elsevier, vol. 63(1), pages 200-211, July.
    4. Eric Wu & Jipan Xie & Chun Wu & Ella Du & Nanxin Li & Ruoding Tan & Yuanli Liu, 2014. "Treatment, Monitoring, and Economic Outcomes of Venous Thromboembolism Among Hospitalized Patients in China," PharmacoEconomics, Springer, vol. 32(3), pages 305-313, March.
    5. Jing Wu & Judy Xu & Gordon Liu & Jiuhong Wu, 2014. "Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals," PharmacoEconomics, Springer, vol. 32(3), pages 293-303, March.
    6. Lizheng Shi & Heidi Yang & Gang Cheng & Qingyue Meng, 2014. "Time Trends and Determinants of Pharmaceutical Expenditure in China (1990–2009)," PharmacoEconomics, Springer, vol. 32(3), pages 257-264, March.
    7. Mingsheng Chen & Lijie Wang & Wen Chen & Luying Zhang & Hongli Jiang & Wenhui Mao, 2014. "Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program," PharmacoEconomics, Springer, vol. 32(3), pages 245-255, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dongxu Li & Min Su & Xi Guo & Weile Zhang & Tianjiao Zhang, 2022. "The Effect of Medical Choice on Health Costs of Middle-Aged and Elderly Patients with Chronic Disease: Based on Principal-Agent Theory," IJERPH, MDPI, vol. 19(13), pages 1-14, June.
    2. Shu Yan & Lizi Pan & Yan Lu & Juan Chen & Ting Zhang & Dongzi Xu & Zhaolian Ouyang, 2023. "Towards Sustainable Drug Supply in China: A Bibliometric Analysis of Drug Reform Policies," Sustainability, MDPI, vol. 15(13), pages 1-20, June.
    3. Shi, Wunan & Wouters, Olivier J. & Liu, Gordon & Mossialos, Elias & Yang, Xiuyun, 2020. "Association between provincial income levels and drug prices in China over the period 2010–2017," Social Science & Medicine, Elsevier, vol. 263(C).
    4. Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
    5. Tatiana Chama Borges Luz & Claudia Garcia Serpa Osorio-de-Castro & Rachel Magarinos-Torres & Bjorn Wettermark, 2017. "Trends in medicines procurement by the Brazilian federal government from 2006 to 2013," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-13, April.
    6. Morgan, Steven G. & Thomson, Paige A. & Daw, Jamie R. & Friesen, Melissa K., 2013. "Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers," Health Policy, Elsevier, vol. 112(3), pages 248-254.
    7. Wenhui Mao & Yunyu Huang & Wen Chen, 2019. "An analysis on rational use and affordability of medicine after the implementation of National Essential Medicines Policy and Zero Mark-up Policy in Hangzhou, China," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    8. Whitty, Jennifer A. & Littlejohns, Peter, 2015. "Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment," Health Policy, Elsevier, vol. 119(2), pages 127-136.
    9. Wenhui Mao & Huyen Vu & Zening Xie & Wen Chen & Shenglan Tang, 2015. "Systematic Review on Irrational Use of Medicines in China and Vietnam," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-16, March.
    10. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    11. Yang Cao & Feng Zhen & Hao Wu, 2019. "Public Transportation Environment and Medical Choice for Chronic Disease: A Case Study of Gaoyou, China," IJERPH, MDPI, vol. 16(9), pages 1-21, May.
    12. Jean Yong & Jaclyn Beca & Jeffrey Hoch, 2013. "The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada," PharmacoEconomics, Springer, vol. 31(3), pages 229-236, March.
    13. R. Tamara Konetzka & Fan Yang & Rachel M. Werner, 2019. "Use of instrumental variables for endogenous treatment at the provider level," Health Economics, John Wiley & Sons, Ltd., vol. 28(5), pages 710-716, May.
    14. Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree, 2012. "Common Drug Review Recommendations," PharmacoEconomics, Springer, vol. 30(3), pages 229-246, March.
    15. Panos Kanavos & Olivier Wouters & John S. F. Wright & Anthony J. G. Barron & Sara M. B. Shah & Corinna Klingler, 2017. "Convergence, Divergence and Hybridity: A Regulatory Governance Perspective on Health Technology Assessment in England and Germany," Global Policy, London School of Economics and Political Science, vol. 8, pages 69-75, March.
    16. Chris Skedgel & Dominika Wranik & Min Hu, 2018. "The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian On," PharmacoEconomics, Springer, vol. 36(4), pages 467-475, April.
    17. Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung, 2018. "Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 5-14, February.
    18. Wang, Qing & Zhang, Donglan & Hou, Zhiyuan, 2016. "Insurance coverage and socioeconomic differences in patient choice between private and public health care providers in China," Social Science & Medicine, Elsevier, vol. 170(C), pages 124-132.
    19. Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith, 2012. "A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand," PharmacoEconomics, Springer, vol. 30(11), pages 1051-1065, November.
    20. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:32:y:2014:i:3:p:231-234. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.